Sign In
Last checked at 
17 Apr 2014 16:41
Annual Information Update
London, 17 April 2014. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Date | Headline |
14/04/2014 | Director/PDMR Shareholding |
07/04/2014 | Blocklisting Interim Review |
07/04/2014 | Total Voting Rights |
02/04/2014 | Successful resolution to US FDA warning letter |
24/03/2014 | Director/PDMR Shareholding |
12/03/2014 | Directorate Change |
12/03/2014 | Final Results |
27/02/2014 | Notification of major interests in shares |
21/02/2014 | Block Listing of Shares |
14/02/2014 | Trading Statement |
11/02/2014 | Directorate Change |
30/12/2013 | Director/PDMR Shareholding |
20/12/2013 | Director/PDMR Shareholding |
20/12/2013 | Director/PDMR Shareholding |
16/12/2013 | Total Voting Rights |
13/12/2013 | Holding(s) in Company |
20/11/2013 | Re Agreement |
11/11/2013 | Director/PDMR Shareholding |
08/11/2013 | Director/PDMR Shareholding |
08/11/2013 | Interim Management Statement |
25/10/2013 | Director/PDMR Shareholding |
23/10/2013 | Holding(s) in Company |
18/10/2013 | Director/PDMR Shareholding |
04/10/2013 | Dividend Declaration |
01/10/2013 | Blocklisting Interim Review |
01/10/2013 | Total Voting Rights |
18/09/2013 | Hikma entering Ethiopian pharmaceutical market |
02/09/2013 | Transaction in Own Shares |
29/08/2013 | Transaction in Own Shares |
21/08/2013 | Interim Results |
31/07/2013 | Director/PDMR Shareholding |
19/07/2013 | Total Voting Rights |
08/07/2013 | Trading Statement |
05/07/2013 | Holding(s) in Company |
01/07/2013 | Signing of Exclusive Agreement with Theravance |
20/06/2013 | Director/PDMR Shareholding |
03/06/2013 | Total Voting Rights |
28/05/2013 | Holding(s) in Company |
23/05/2013 | Director/PDMR Shareholding |
21/05/2013 | Director/PDMR Shareholding |
20/05/2013 | Director/PDMR Shareholding |
16/05/2013 | Result of AGM |
16/05/2013 | Interim Management Statement |
10/05/2013 | Director/PDMR Shareholding |
02/05/2013 | Director/PDMR Shareholding |
23/04/2013 | Director/PDMR Shareholding |
18/04/2013 | Director/PDMR Shareholding |
17/04/2013 | Hikma update on global Injectables business |
10/04/2013 | Annual Financial Report |
All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com).
Documents filed with the Financial Services Authority
The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.
Date | Document |
10 April 2014 | Annual Report and Accounts 2013 |
10 April 2014 | Notice of 2014 Annual General Meeting |
10 April 2014 | Proxy forms for the 2014 Annual General Meeting |
10 April 2013 | Annual Report and Accounts 2012 |
10 April 2013 | Notice of 2013 Annual General Meeting |
10 April 2013 | Proxy forms for the 2013 Annual General Meeting |
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.
Date Filed | Form | Description |
05/04/2013 | SH01 | Statement of Capital GBP 19,748,436.90 |
24/05/2013 | RES10 | Authorised Allotment of Shares and Debentures |
02/07/2013 | AA | Group of Companies' Accounts made up to 31/12/12 |
19/07/2013 | SH01 | Statement of Capital GBP 19,794,212.80 |
11/09/2013 | AR01 | Annual Return - No Member List |
25/09/2013 | MR01 | Registration of a Charge / Charge Code 055579340002 |
07/10/2013 | SH03 | Return of Purchase of Own Shares - Treasury Capital GBP 21,000 |
10/10/2013 | SH01 | Statement of Capital GBP 19,796,502.80 |
07/04/2014 | SH01 | Statement of Capital GBP 19,815,699.70 |
07/04/2014 | SH01 | Statement of Capital GBP 19,815,699.70 |
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk.
Further Information
Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.
Peter Speirs
Company Secretary17 April 2014
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.
Follow the stocks
